Does Wegovy Decrease LDL Cholesterol?
No, Wegovy (semaglutide) does not increase your LDL cholesterol—in fact, it significantly decreases it. Multiple high-quality real-world studies and clinical data consistently demonstrate that semaglutide therapy leads to meaningful reductions in LDL cholesterol levels 1, 2.
Evidence for LDL Reduction
The most recent and robust real-world evidence shows:
A 2026 US retrospective cohort study (SMILE) with over 25,000 semaglutide 2.4 mg users demonstrated a significant reduction in LDL cholesterol of -7.7 mg/dL at 12 months compared to non-users (p < 0.001) 1. This same study also showed improvements in triglycerides (-28.6 mg/dL) and HDL cholesterol (+1.9 mg/dL).
A 2026 Russian study of obese patients on semaglutide for 8 months found statistically significant decreases in LDL cholesterol (p=0.001), total cholesterol (p=0.001), and triglycerides (p<0.001), alongside increases in HDL cholesterol (p<0.01) 2.
A 2026 comparative study showed semaglutide was associated with greater LDL cholesterol improvement compared to dulaglutide when combined with hypocaloric diet 3.
Another 2026 Indian tertiary care study confirmed LDL cholesterol declined significantly from 92.03 mg/dL to 78.93 mg/dL after six months of semaglutide therapy (p <0.05) 4.
Comprehensive Cardiometabolic Benefits
Beyond LDL reduction, Wegovy provides multiple cardiovascular benefits:
- Reduced cardiovascular risk: The SMILE study demonstrated a greater reduction in 10-year ASCVD risk score (-0.7% vs. +0.3% in non-users; between-group difference -1.0%, p < 0.001) 1
- Lower incidence of cardiovascular events: Significantly reduced risks for incident hypertension, ASCVD, heart failure, and CVD (hazard ratios 0.45-0.75) 1
- Improved blood pressure: Systolic blood pressure reduction of -6.2 mmHg 1
Clinical Context
The lipid-lowering effects occur alongside:
- Substantial weight loss (mean BMI reduction of -4.1 kg/m² at 12 months) 1
- Improved glycemic control (HbA1c reduction of -0.4%) 1
- Favorable changes in adipokine profile (increased adiponectin, decreased leptin) 2
Important Caveats
While Wegovy improves your lipid profile, be aware of common side effects:
- Gastrointestinal symptoms (nausea 44%, diarrhea 30%, vomiting 24%) are common but typically mild and improve with gradual dose titration 5
- Monitor for rare but serious adverse events including pancreatitis, gallbladder disease, and acute kidney injury 5
- Heart rate increases can occur; monitor regularly and discontinue if sustained elevation develops 5
The evidence is clear and consistent: Wegovy decreases, not increases, LDL cholesterol as part of its broader cardiometabolic benefits.